- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01152229
Platelet Reactivity In Patients With Nuisance Bleeding On A Thienopyridine (PLACID)
August 1, 2011 updated by: Medstar Health Research Institute
The objective is to describe and quantify levels of platelet reactivity in three different cohorts of patients taking thienopyridine: patients who report nuisance bleeding, patients who report alarming bleeding, and patients who report no nuisance or alarming bleeding.
The investigators hypothesize that patients with nuisance or alarming bleeding events on maintenance thienopyridine therapy will have lower levels of platelet reactivity than patients without nuisance or alarming bleeding on thienopyridine therapy.
Study Overview
Status
Completed
Conditions
Study Type
Observational
Enrollment (Anticipated)
300
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20010
- Washington Hospital Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Patients who have undergone PCI and have reported no bleeding, nuisance bleeding or alarming bleeding.
Description
Inclusion Criteria:
- Patients 18 years or older from both genders
- Underwent PCI within the last year
- Taking maintenance dose of clopidogrel 75 mg once a day or prasugrel 10 mg once a day for at least five days
Exclusion Criteria:
- Known allergies to aspirin, clopidogrel, or prasugrel.
- Use of a glycoprotein (GP)IIb/IIIa inhibitor within 8 hours of the blood draw.
- Patient known to be pregnant or lactating
- Patient with known history of anemia, thrombocytopenia, bleeding disorder, or currently active bleeding
- On warfarin therapy at the time of blood draw
- Known blood transfusion within the preceding 10 days of the blood draw
- Patients treated with non-steroidal anti-inflammatory drugs (NSAIDS, not to include aspirin) within the previous 5 days
- Any significant medical condition that, in the investigator's opinion, may interfere with the patient's optimal participation in the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
|---|
|
nuisance bleeding
|
|
alarming bleeding
|
|
maintenance therapy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
platelet reactivity
Time Frame: post percutaneous coronary intervention (PCI) while still on clopidogrel
|
Level of platelet reactivity as assessed with the Chrono-Log Lumi-Aggregometer, which measures levels of light transmittance after stimulation with ADP to estimate levels of platelet aggregation.
|
post percutaneous coronary intervention (PCI) while still on clopidogrel
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Platelet reactivity
Time Frame: post PCI while still on clopidogrel
|
|
post PCI while still on clopidogrel
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Michael Gaglia, MD, Cardiovascular Research Institute
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2010
Primary Completion (Actual)
June 1, 2011
Study Completion (Actual)
July 1, 2011
Study Registration Dates
First Submitted
May 28, 2010
First Submitted That Met QC Criteria
June 25, 2010
First Posted (Estimate)
June 29, 2010
Study Record Updates
Last Update Posted (Estimate)
August 3, 2011
Last Update Submitted That Met QC Criteria
August 1, 2011
Last Verified
August 1, 2011
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PLACID
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.